Smita Prakash Kakad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Smita Prakash Kakad has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Sanjay J. Kshirsagar
Department of Pharmaceutics, MET Institute of Pharmacy, Savitribai Phule Pune University, Adgaon, Nashik, Maharashtra, India
4 shared publications- Neelam Laxman Dashputre
Department of Pharmacology, MET’s Institute of Pharmacy, Bhujbal Knowledge, City, Adgaon, Nashik Maharashtra, India
2 shared publications - Umesh D. Laddha
MET’s Institute of Pharmacy, Affiliated to Savitribai Phule Pune University, BKC, Adgaon, Nashik, India
2 shared publications Anjali B. Tajanpure
Department of Pharmacology, MET's Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nasik, 422003, Maharashtra, India
1 shared publicationAnjali Tajanpure
Department of Pharmaceutics, MET Institute of Pharmacy, Savitribai Phule Pune University, Adgaon, Nashik, Maharashtra, India
1 shared publication- Eknath D. Ahire
MET’s Institute of Pharmacy, BKC, Affiliated to Savitribai Phule Pune University, Adgaon Nashik, Maharashtra, India- 422003
1 shared publication
Latest Publications
- Open Access
- 27 May 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 7
An overview on developing the formulation to keep away the food impact on absorption
- 27 May 2025
- Published by Elsevier in Next Nanotechnology
- Vol. 7
Open AccessAn overview on developing the formulation to keep away the food impact on absorption
- Open Access
- 30 March 2024
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 21 (1) , 109-121
Fabrication of Amisulpride Nanosuspension for Nose to Brain Delivery in the Potential Antipsychotic Treatment
Background: This research was aimed with the development of antipsychotic drug delivery for olfactory administration which could deliver drug to the brain. Amisulpride is a psychoactive drug that belongs to the benzamide derivatives class. It enhances dopaminergic neurotransmission by inhibiting presynaptic dopamine D2/D3 auto receptors selectively at lower dosages. Method: The nanosuspension was prepared by media milling technique for nose to brain delivery. The nose to brain delivery developed an effective route to bypass the BBB and deliver the drug to the brain. Factorial design was used for the designing and optimizing formulation based on various process and formulation factors. The optimized batch further analyzed to determine particle size, PDI, zeta potential, and drug content. With appropriate selection of process parameters like speed and bead amount. The media milling method is one of the effective methodology to reduce particle size and with the help of stabilizers nanoparticles could be stabilised. Result: The average particle size range of nanosuspension batch was observed 100-150 nm with a polydispersity index of 0.0927, Zeta potential +39.14 mV and drug content 88.12 ± 2 %. Conclusion: Intranasal administration is a promising alternative for bypassing the blood-brain barrier, reducing the adverse effects, and lowering the doses.
- 30 March 2024
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 21 (1) , 109-121
Open AccessFabrication of Amisulpride Nanosuspension for Nose to Brain Delivery in the Potential Antipsychotic Treatment
Background: This research was aimed with the development of antipsychotic drug delivery for olfactory administration which could deliver drug to the brain. Amisulpride is a psychoactive drug that belongs to the benzamide derivatives class. It enhances dopaminergic neurotransmission by inhibiting presynaptic dopamine D2/D3 auto receptors selectively at lower dosages. Method: The nanosuspension was prepared by media milling technique for nose to brain delivery. The nose to brain delivery developed an effective route to bypass the BBB and deliver the drug to the brain. Factorial design was used for the designing and optimizing formulation based on various process and formulation factors. The optimized batch further analyzed to determine particle size, PDI, zeta potential, and drug content. With appropriate selection of process parameters like speed and bead amount. The media milling method is one of the effective methodology to reduce particle size and with the help of stabilizers nanoparticles could be stabilised. Result: The average particle size range of nanosuspension batch was observed 100-150 nm with a polydispersity index of 0.0927, Zeta potential +39.14 mV and drug content 88.12 ± 2 %. Conclusion: Intranasal administration is a promising alternative for bypassing the blood-brain barrier, reducing the adverse effects, and lowering the doses.
- RetractedOpen Access
RETRACTED: Potential therapeutic effects of naringin loaded PLGA nanoparticles for the management of Alzheimer's disease: In vitro, ex vivo and in vivo investigation
- Open Access
- 26 November 2022
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 11 (1) , 1-10
Development of nanoemulsion of antiviral drug for brain targeting in the treatment of neuro-AIDS
Background: Delivery of drugs via the nasal route directly to the brain utilizing the olfactory pathway is purportedly known to be a more efficient method to deliver neuro-therapeutics to the brain by circumventing the BBB, thereby increasing the bioavailability of these drugs in the brain. The main objective of the project work is to improve the bioavailability of the antiretroviral drug and to minimize the side effects of this therapy which are observed at the higher side in the chronic HIV treatment. The advantage of nasal drug delivery is its noninvasiveness and self-administration. Nanoformulation provides fast onset of action and helps to achieve site-specific delivery. In the current work, nanoemulsion formulation was developed with a ternary phase system. In vitro characterization of nanoemulsion was performed. Result: Optimized batch B2 had a zeta potential of − 18.7 mV showing a stable emulsion system and a particle size of 156.2 nmin desirable size range. Batch B2 has the least variation in globule size with PDI 0.463. Results from ex vivo studies revealed that developed nanoemulsion (B2) possessed a higher rate of drug release compared to other formulations. Conclusion: Phase diagrams indicated more width of the nanoemulsion region with an increase in surfactant ratio. Stable nanoemulsion was prepared with a combination of surfactant and co-surfactants. Nanoemulsions could prove one of the best alternatives for brain delivery of potent medications. Graphical
- 26 November 2022
- Published by Springer Nature in Beni-Suef University Journal of Basic and Applied Sciences
- Vol. 11 (1) , 1-10
Open AccessDevelopment of nanoemulsion of antiviral drug for brain targeting in the treatment of neuro-AIDS
Background: Delivery of drugs via the nasal route directly to the brain utilizing the olfactory pathway is purportedly known to be a more efficient method to deliver neuro-therapeutics to the brain by circumventing the BBB, thereby increasing the bioavailability of these drugs in the brain. The main objective of the project work is to improve the bioavailability of the antiretroviral drug and to minimize the side effects of this therapy which are observed at the higher side in the chronic HIV treatment. The advantage of nasal drug delivery is its noninvasiveness and self-administration. Nanoformulation provides fast onset of action and helps to achieve site-specific delivery. In the current work, nanoemulsion formulation was developed with a ternary phase system. In vitro characterization of nanoemulsion was performed. Result: Optimized batch B2 had a zeta potential of − 18.7 mV showing a stable emulsion system and a particle size of 156.2 nmin desirable size range. Batch B2 has the least variation in globule size with PDI 0.463. Results from ex vivo studies revealed that developed nanoemulsion (B2) possessed a higher rate of drug release compared to other formulations. Conclusion: Phase diagrams indicated more width of the nanoemulsion region with an increase in surfactant ratio. Stable nanoemulsion was prepared with a combination of surfactant and co-surfactants. Nanoemulsions could prove one of the best alternatives for brain delivery of potent medications. Graphical
- Open Access
- 7 January 2021
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 7 (1) , 1-7
Development of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
Background: The brain is the potential viral reservoir, and estimating the antiviral drug concentration in the brain is a hurdle to the researchers as very few animal models are available for this study. The objective of the study was to develop and validate the RP-HPLC method for the estimation of antiviral drug efavirenz (EFV) in the brain of healthy Wistar rats. EFV was the first-line antiretroviral medication. The optimized HPLC condition used for the analysis had the mobile phase methanol to water (9:1) ratio. The flow rate was set at 0.8 mL/min, while the detection wavelength was 248 nm. Results: The retention time was found to be 5.7 min, and the % RSD was found within the limit. Recovery was found to be nearly 78%. The validation results were found to be within the limit range; hence, the obtained method was accurate, specific, rapid, and repeatable for estimation of EFV in the brain. Conclusion: This method for estimation of EFV in the rat brain can be applicable for pharmacokinetic and toxicology study of EFV in the brain after administration of EFV to rats. Graphical .
- 7 January 2021
- Published by Springer Nature in Future Journal of Pharmaceutical Sciences
- Vol. 7 (1) , 1-7
Open AccessDevelopment of reverse phase high-performance liquid chromatographic method for the estimation of HIV non-nucleoside reverse transcriptase inhibitor drug efavirenz in the rat brain
Background: The brain is the potential viral reservoir, and estimating the antiviral drug concentration in the brain is a hurdle to the researchers as very few animal models are available for this study. The objective of the study was to develop and validate the RP-HPLC method for the estimation of antiviral drug efavirenz (EFV) in the brain of healthy Wistar rats. EFV was the first-line antiretroviral medication. The optimized HPLC condition used for the analysis had the mobile phase methanol to water (9:1) ratio. The flow rate was set at 0.8 mL/min, while the detection wavelength was 248 nm. Results: The retention time was found to be 5.7 min, and the % RSD was found within the limit. Recovery was found to be nearly 78%. The validation results were found to be within the limit range; hence, the obtained method was accurate, specific, rapid, and repeatable for estimation of EFV in the brain. Conclusion: This method for estimation of EFV in the rat brain can be applicable for pharmacokinetic and toxicology study of EFV in the brain after administration of EFV to rats. Graphical .
- 1 October 2020
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 15 (5) , 469-481
Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Introduction: The infiltration of HIV into the brain alters the functions of the nervous system known as Neuro-AIDS. It leads to neuronal defects clinically manifested by motor and cognitive dysfunctions.Materials and Methods: Current antiretroviral therapy can prevent viral replication but cannot cure the disease completely. HAART-Highly active antiretroviral therapy is used for the treatment of HIV infection. Challenges in neuro-AIDS therapy are as shown in the graphical One of the challenges is latent viral reservoirs like the brain; which act as a sanctuary site for viruses. Nearly ~50% of HIV patients show neuropathological signs. Nervous system related disorders, including AIDS dementia, sensory neuropathy, and myelopathy have a 25% of prevalence in patients having access to a highly active combination of antiretroviral therapy.Results and Conclusion: Brain is one of the viral sanctuary sites for HIV. The current need of neuro-AIDS therapy is to target the brain as a viral reservoir. Drugs should cross or bypass the blood-brain barrier to reach the brain with effective concentrations. Current research on novel drug delivery approaches may prove helpful in treating neuro-AIDS and related disorders effectively.
- 1 October 2020
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 15 (5) , 469-481
Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Introduction: The infiltration of HIV into the brain alters the functions of the nervous system known as Neuro-AIDS. It leads to neuronal defects clinically manifested by motor and cognitive dysfunctions.Materials and Methods: Current antiretroviral therapy can prevent viral replication but cannot cure the disease completely. HAART-Highly active antiretroviral therapy is used for the treatment of HIV infection. Challenges in neuro-AIDS therapy are as shown in the graphical One of the challenges is latent viral reservoirs like the brain; which act as a sanctuary site for viruses. Nearly ~50% of HIV patients show neuropathological signs. Nervous system related disorders, including AIDS dementia, sensory neuropathy, and myelopathy have a 25% of prevalence in patients having access to a highly active combination of antiretroviral therapy.Results and Conclusion: Brain is one of the viral sanctuary sites for HIV. The current need of neuro-AIDS therapy is to target the brain as a viral reservoir. Drugs should cross or bypass the blood-brain barrier to reach the brain with effective concentrations. Current research on novel drug delivery approaches may prove helpful in treating neuro-AIDS and related disorders effectively.